Development of a Single Construct System for Site-Directed RNA Editing Using MS2-ADAR.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
13 Jul 2020
Historique:
received: 07 05 2020
revised: 08 07 2020
accepted: 08 07 2020
entrez: 17 7 2020
pubmed: 17 7 2020
medline: 3 3 2021
Statut: epublish

Résumé

Site-directed RNA editing (SDRE) technologies have great potential for treating genetic diseases caused by point mutations. Our group and other researchers have developed SDRE methods utilizing adenosine deaminases acting on RNA (ADARs) and guide RNAs recruiting ADARs to target RNAs bearing point mutations. In general, efficient SDRE relies on introducing numerous guide RNAs relative to target genes. However, achieving a large ratio is not possible for gene therapy applications. In order to achieve a realistic ratio, we herein developed a system that can introduce an equal number of genes and guide RNAs into cultured cells using a fusion protein comprising an ADAR fragment and a plasmid vector containing one copy of each gene on a single construct. We transfected the single construct into HEK293T cells and achieved relatively high efficiency (up to 42%). The results demonstrate that efficient SDRE is possible when the copy number is similar for all three factors (target gene, guide RNA, and ADAR enzyme). This method is expected to be capable of highly efficient gene repair

Identifiants

pubmed: 32668759
pii: ijms21144943
doi: 10.3390/ijms21144943
pmc: PMC7404196
pii:
doi:

Substances chimiques

RNA, Guide 0
Recombinant Fusion Proteins 0
Viral Proteins 0
enhanced green fluorescent protein 0
Green Fluorescent Proteins 147336-22-9
Adenosine Deaminase EC 3.5.4.4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 26670167, 17H02204 and 18K19288

Références

Hum Gene Ther. 2015 Jul;26(7):443-51
pubmed: 26068008
Nat Protoc. 2014 Oct;9(10):2395-410
pubmed: 25232936
Gene Ther. 2017 Dec;24(12):779-786
pubmed: 28984845
Cell. 1998 Jul 24;94(2):193-204
pubmed: 9695948
Curr Opin Biotechnol. 2019 Feb;55:74-80
pubmed: 30193161
Nature. 2017 Nov 23;551(7681):464-471
pubmed: 29160308
Nat Methods. 2018 Jul;15(7):535-538
pubmed: 29967493
EMBO Rep. 2000 Nov;1(5):411-5
pubmed: 11258480
Genome Res. 2015 Oct;25(10):1442-55
pubmed: 26430154
Nucleic Acids Res. 2016 Dec 1;44(21):e157
pubmed: 27557710
Hum Mol Genet. 2014 Sep 15;23(R1):R40-6
pubmed: 24651067
RNA. 2004 Nov;10(11):1776-82
pubmed: 15496523
Nucleic Acids Res. 1996 Jun 15;24(12):2352-9
pubmed: 8710507
Nat Biotechnol. 2014 Apr;32(4):347-55
pubmed: 24584096
Blood. 2009 Sep 3;114(10):2077-86
pubmed: 19506302
Mol Plant. 2017 Mar 6;10(3):526-529
pubmed: 27940306
N Engl J Med. 2010 Oct 7;363(15):1429-37
pubmed: 20925545
Biochemistry. 2019 Apr 16;58(15):1947-1957
pubmed: 30943016
EMBO J. 1993 Feb;12(2):595-600
pubmed: 8440248
Methods. 2019 Mar 1;156:16-24
pubmed: 30502398
Nat Biotechnol. 2019 Feb;37(2):133-138
pubmed: 30692694
Nature. 2019 May;569(7756):433-437
pubmed: 30995674
RNA Biol. 2018 Jan 2;15(1):104-114
pubmed: 29099293
Science. 2017 Nov 24;358(6366):1019-1027
pubmed: 29070703
Nat Med. 2015 Feb;21(2):121-31
pubmed: 25654603
Nature. 2016 Apr 20;533(7603):420-4
pubmed: 27096365
Protein Eng Des Sel. 2018 Dec 1;31(12):471-478
pubmed: 31120126
J Biol Chem. 1994 Mar 25;269(12):9006-10
pubmed: 8132638
Mol Ther. 2016 Mar;24(3):430-46
pubmed: 26755333
Mol Cell Proteomics. 2011 Apr;10(4):M110.007385
pubmed: 21285413
Nat Biotechnol. 2014 Jun;32(6):577-582
pubmed: 24770324
Curr Gene Ther. 2019;19(1):31-39
pubmed: 30426900
Gene. 2004 Aug 4;337:71-7
pubmed: 15276203
Nat Commun. 2011;2:319
pubmed: 21587236
Science. 2019 Jul 26;365(6451):382-386
pubmed: 31296651
Nat Biotechnol. 2019 Sep;37(9):1059-1069
pubmed: 31308540
RNA. 2005 Feb;11(2):227-33
pubmed: 15613539
Nat Methods. 2019 Mar;16(3):239-242
pubmed: 30737497
BMC Res Notes. 2012 Jan 24;5:63
pubmed: 22269019

Auteurs

Tetsuto Tohama (T)

Area of Bioscience and Biotechnology, Japan Advanced Institute of Science and Technology, 1-1 Asahidai, Nomi, Ishikawa 923-1292, Japan.

Matomo Sakari (M)

Area of Bioscience and Biotechnology, Japan Advanced Institute of Science and Technology, 1-1 Asahidai, Nomi, Ishikawa 923-1292, Japan.

Toshifumi Tsukahara (T)

Area of Bioscience and Biotechnology, Japan Advanced Institute of Science and Technology, 1-1 Asahidai, Nomi, Ishikawa 923-1292, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH